Metabolic marker profiling of circulating tumour cells in NSCLC patients treated with osimertinib: focus on MCT1 and MCT4

20260 citationsJournal Articlegold Open Access

Authors

MCT1 and MCT4 are overexpressed in CTCs from NSCLC patients, supporting their potential as prognostic biomarkers and therapeutic targets.

Published in: Therapeutic Advances in Medical Oncology

Volume 18, pp. 17588359261416422-17588359261416422

Field-Weighted Citation Impact: 0.00